What is Germitec?
Germitec is a forward-thinking company dedicated to elevating healthcare standards by mitigating cross-contamination risks. The company specializes in automated UV-C High-Level Disinfection for ultrasound probes, offering a fast, safe, and environmentally conscious solution. Their mission centers on enhancing patient safety and preventing Healthcare-Associated Infections by improving hygiene practices and probe disinfection protocols. Key product lines include Chronos for endocavitary and external ultrasound probes, Antigermix for other probe types, and Yuvee technology, all designed to ensure superior UV-C disinfection.
How much funding has Germitec raised?
Germitec has raised a total of $30M across 1 funding round:
Other Financing Round
$30M
Other Financing Round (2025): $30M with participation from Eurazeo
Key Investors in Germitec
Eurazeo
Eurazeo, a prominent global investment company founded in 1969, offers deep sector expertise across private equity, venture capital, real estate, and private debt. They support companies of all sizes in their growth and development, providing a gateway to global markets and a stable foundation for transformational expansion.
What's next for Germitec?
With this major enterprise-level funding, Germitec is poised for significant expansion and further innovation in the critical area of medical device disinfection. The strategic investment will likely fuel advancements in their UV-C technology, broaden market reach, and enhance their product development pipeline. This capital will enable Germitec to solidify its position as a leader in preventing healthcare-associated infections, driving the adoption of advanced hygiene solutions across global healthcare institutions.
See full Germitec company page
